ALFA Finder| Revenue growth | 8% YoY for FY26. |
|---|---|
| Margins | FY26 EBITDA margin improved 69 bps to 28%. |
| Order book | Targeting 200+ CT/MRI centres upon completion of current book. |
| Demand visibility | Expanding network to 7-8 states and newer geographies. |
| Management confidence | Strong focus on 'Everyone Can Afford' pricing strategy. |
Growth
FY26 Revenue grew 8% to ₹7.7bn; EBITDA up 10% to ₹2.1bn. PAT surged 31% including a ₹221.75mn valuation gain.
Outlook
Targeting 200+ CT/MRI centers and 5,000+ collection centers. Rajasthan project to significantly scale pathology network.
Risks
Business cyclicity impacting quarterly performance and competitive pricing pressures in the diagnostic industry.
Earnings Call filed with BSE, NSE: KRSNAA. Summary written with AI assistance from the document.
Krsnaa Diagnostics Ltd: key numbers
- Share price
- ₹508.50
- Market cap
- ₹1,650 Cr
- Revenue (annual)
- ₹772.8 Cr
- Net profit (annual)
- ₹101.4 Cr
- P/E (TTM)
- 16.8×Sector 54.5×
- Promoter holding
- 27.11%+0.00% QoQ
- FII holding
- 3.84%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krsnaa Diagnostics Ltd
All →Krsnaa Diagnostics Other Announcement
Krsnaa Diagnostics informs exchanges that its RTA, KFin Technologies, will shift its corporate office effective December 1, 2026. The registered office and the company's own operations are unaffected.
Krsnaa Diagnostics Convertible Warrants
Krsnaa's auditor certified upfront consideration for 16.21 lakh promoter warrants at Rs.566 each, totalling Rs.91.75 Crore issue value. Certificate confirms upfront money came directly from allottees' accounts.
- Value
- ₹91.75 Cr
Krsnaa Diagnostics Bags New Order from Municipal Corporation of Delhi
Krsnaa Diagnostics secured a 15-year cash-based PPP project from the Municipal Corporation of Delhi. The contract involves establishing CT Scan and MRI facilities at three public hospitals.
- From
- Municipal Corporation of Delhi (MCD)
- Execution
- 15 years
- diagnostic facilities
- 3.0 project sites
Krsnaa Diagnostics Earnings Call Transcript: Key Takeaways
Krsnaa hit ₹500 Cr H1 revenue, but heavy Rajasthan ramp-up costs and government receivable delays (₹472 Cr) are squeezing margins and PAT.
- Call
- Guides 45% growth
Krsnaa Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 2,710 Mn (+32% YoY) and PAT INR 246 Mn (+3%). EBITDA margin fell to 27% from 29% on Rajasthan fixed costs.
Krsnaa Diagnostics Results Update
Krsnaa Diagnostics reported record Q2 revenue of Rs 2,710 million, up 32% year on year. H1 PAT fell to Rs 411 million on Rajasthan project costs.